Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies

Daniel Sasca, Haiyang Yun, George Giotopoulos, Jakub Szybinski, Theo Evan, Nicola K. Wilson, Moritz Gerstung, Paolo Gallipoli, Anthony R. Green, Robert Hills, Nigel Russell, Cameron S. Osborne, Elli Papaemmanuil, Berthold Göttgens, Peter Campbell, Brian J. P. Huntly

Blood (2019) 134 (24): 2195–2208.

https://doi.org/10.1182/blood.2019001553

Published: 2019

Includes: Supplemental data

Journal Articles

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

Nigel Russell, Alan Burnett, Robert Hills, Sophie Betteridge, Mike Dennis, Jelena Jovanovic, Richard Dillon, David Grimwade

Blood (2018) 132 (13): 1452–1454.

https://doi.org/10.1182/blood-2018-05-851824

Published: 2018

Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett

Blood (2017) 129 (9): 1143–1154.

https://doi.org/10.1182/blood-2016-07-730648

Published: 2017

Includes: Supplemental data

Journal Articles

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mike Dennis, Nigel Russell, Robert K. Hills, Claire Hemmaway, Nicki Panoskaltsis, Mary-Frances McMullin, Lars Kjeldsen, Helen Dignum, Ian F. Thomas, Richard E. Clark, Don Milligan, Alan K. Burnett

Blood (2015) 125 (19): 2923–2932.

https://doi.org/10.1182/blood-2014-10-608117

Published: 2015

Includes: Supplemental data

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT

Blood (2014) 124 (21): 2561.

https://doi.org/10.1182/blood.V124.21.2561.2561

Published: 2014

Journal Articles

The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood

Blood (2014) 124 (21): 681.

https://doi.org/10.1182/blood.V124.21.681.681

Published: 2014

Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 7.

https://doi.org/10.1182/blood.V124.21.7.7

Published: 2014

Journal Articles

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

Blood (2014) 124 (21): 70.

https://doi.org/10.1182/blood.V124.21.70.70

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Alan K Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jamie Cavenagh, Jonathan Kell, MD MB, Gail Jones, Asim Khwaja, FRCPath, Mary Frances McMullin, MDFRCPath,FRCP, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 2308.

https://doi.org/10.1182/blood.V124.21.2308.2308

Published: 2014

Journal Articles

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

John Jones, MD, Charlotte Pawlyn, MBBChir, Annamaria Brioli, David A Cairns, PhD, Ana Quartillo, Rachel Sigsworth, Helen Howard, PhD, Corinne Collett, Jacqueline Ouzman, PhD, Walter Gregory, PhD, Nigel Russell, Graham H Jackson, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 4744.

https://doi.org/10.1182/blood.V124.21.4744.4744

Published: 2014

Journal Articles

Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Sonja G Genadieva Stavrik, MDPhD, Ariane Boumendil, Kirsty Thomson, Javier Briones, MD, Paolo Corradini, MD, Andrea Bacigalupo, MD, Gerard Socie, Guiseppe Bandini, Herve Finel, Andrea Velardi, MD, Michael Potter, PhD, Bruno Benedetto, Luca Castagna, MD, Charles Craddock, MDPhD, Nigel Russell, Peter Dreger, MD, Sureda Anna

Blood (2014) 124 (21): 2562.

https://doi.org/10.1182/blood.V124.21.2562.2562

Published: 2014

Journal Articles

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

Blood (2014) 124 (21): 15.

https://doi.org/10.1182/blood.V124.21.15.15

Published: 2014

Journal Articles

Patient/Donor CMV Matching Is a Critical Determinant of Survival in Unrelated Donor Haematopoietic Stem Cell Transplantation

Bronwen E. Shaw, PhD MRCP, FRCPath, Neema P Mayor, Szydlo Richard, Will P Bultitude, Kirkland Keiren, Perry Julia, Wilson Marie, Andrew Clark, Stephen Mackinnon, David I Marks, Antonio Pagliuca, MD FRCP, FRCPath, Michael Potter, PhD, Nigel Russell, Kirsty Thomson, J. Alejandro Madrigal, MD PhD, Steven GE Marsh, PhD

Blood (2014) 124 (21): 1207.

https://doi.org/10.1182/blood.V124.21.1207.1207

Published: 2014

Journal Articles

Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma

Yasmin Reyal, Irfan Kayani, Ronjon Chakraverty, Adrian Bloor, PhD FRCPath, Christopher P Fox, Kirsty Thomson, Adele K. Fielding, Ben Taylor, Mark Bishton, Emma Morris, Nigel Russell, Stephen Mackinnon, Karl S Peggs

Blood (2014) 124 (21): 1225.

https://doi.org/10.1182/blood.V124.21.1225.1225

Published: 2014

Journal Articles

Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord

John A Snowden, MD, FRCP, FRCPath, Robert Danby, MRCP, Annalisa Ruggeri, MD, David I Marks, Rachael E Hough, MD, Antonio Pagliuca, Michael Potter, MD PhD, Nigel Russell, MD, Charles Craddock, MD DPhil, Andrew Clark, Eliane Gluckman, MD, Gordon Cook, MD, PhD, Bronwen E. Shaw, MBChB, MRCP, PhD, FRCPath, Vanderson Rocha, MD, PhD

Blood (2013) 122 (21): 3394.

https://doi.org/10.1182/blood.V122.21.3394.3394

Published: 2013

NARROW

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT

The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

Patient/Donor CMV Matching Is a Critical Determinant of Survival in Unrelated Donor Haematopoietic Stem Cell Transplantation

Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma

Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only